Proteon & Artara Therapeutics Agree to Combine in All-Stock Deal

Proteon Therapeutics agreed to merge with ArTara Therapeutics, a private clinical stage biopharmaceutical company, in an all-stock transaction.

• The combined company to operate under the name ArTara Therapeutics and trade on Nasdaq under ticker symbol “TARA”
• A syndicate of healthcare dedicated investors have concurrently entered into a stock purchase agreement to invest $42.5 million in the combined company
• The financing will help fund the development of ArTara’s lead assets TARA-002 and IV Choline Chloride
• The combined company will be led by Jesse Shefferman, ArTara Chief Executive Officer

To view the source of this information click here

To contact the reporter ...